Milestone Pharmaceuticals shares surge 17.82% intraday as CARDAMYST added to Express Scripts national formularies.

Milestone Pharmaceuticals surged 17.82% intraday after announcing that Express Scripts added its FDA-approved drug CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. This marks the first contracted formulary acceptance of CARDAMYST by a major payor, significantly expanding access for insured patients in the U.S. The news reinforced the company’s progress in commercializing its flagship product and signaled growing adoption potential with other insurers. Meanwhile, news about Milestone Scientific (MLSS) related to financial results and restructuring efforts did not influence the movement in Milestone Pharmaceuticals (MIST).